A novel and safe approach for treating cognitive disorders
January 10, 2022 Non RegulatoryUmecrine Cognition presents data showing a reduction of neuroinflammation following treatment with golexanoloneStockholm, January 10, 2022 – Umecrine Cognition AB today announced nonclinical results showing that its clinical drug candidate golexanolone...
November 3, 2021 Non RegulatoryUmecrine Cognition presents data supporting a new predictive biomarker in patients with primary biliary cholangitis at the AASLD International Liver Meeting 2021STOCKHOLM – Umecrine Cognition AB today announces new scientific results for its drug candidate golexanolone, linking the drug target allopregnanolone to cognitive symptoms in patients with primary biliary cholangitis. The data will be presented at The Liver Meeting Digital ExperienceTM 2021, the premier Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), being held November 12-15.
October 18, 2021 Non RegulatoryUmecrine Cognition enters collaboration with University College London to increase insights around golexanoloneSTOCKHOLM – October 18, 2021. Umecrine Cognition AB today announces the establishment of a collaboration with Professor Trevor G Smart and his research group at University College London. The scope of the collaboration will include molecular and behavioral investigations of Umecrine Cognition’s most advanced drug candidate golexanolone.
Our drug projects
GABAA receptor modulating steroid antagonists: our scientific focus
Our lead product candidate, golexanolone, is a novel small molecule GABAA receptor-modulating steroid antagonist in development for the treatment of neurological disorders caused by overactivation of GABA-A receptors by the neurosteroid allopregnanolone.